Is Diabetes Making People Age Faster? What the New Science Reveals

From diabetesincontrol.com

For decades, scientists have known that people with type 2 diabetes face a higher risk of heart disease, kidney disease, cognitive decline, and other age-related conditions. However, emerging research suggests these complications may be linked to something even more fundamental: accelerated biological aging in diabetes. In other words, diabetes may not simply increase the risk of diseases associated with aging. It may also cause the body to age faster at the cellular level.

Today, researchers are using advanced biomarkers and epigenetic tools to understand how chronic metabolic stress affects aging. As a result, a clearer picture is emerging of the biological mechanisms that connect diabetes, inflammation, cellular damage, and age-related decline.

Biological Age and Why It Matters

Most people think of age as the number of years they have lived. This is known as chronological age. However, biological age reflects how well the body’s cells, tissues, and organs are functioning compared with that number.

Two people can both be 60 years old and still have very different biological ages. One may have the health profile of someone much younger, while the other may show signs of faster physical decline. Therefore, researchers increasingly believe that biological age may offer a clearer view of long-term health risks.

This concept has become especially important in diabetes research. Studies suggest that people with type 2 diabetes often show aging markers that exceed what would be expected based on chronological age alone. Consequently, scientists are investigating whether diabetes-related biological aging contributes directly to complications, frailty, and reduced lifespan.

Moreover, biological aging is not caused by one single factor. Instead, it reflects a complex mix of genetics, lifestyle, inflammation, metabolic health, and environmental exposures. Diabetes appears to affect many of these pathways at the same time.

How Diabetes May Accelerate Aging at the Cellular Level

Several biological mechanisms may help explain accelerated aging in people with diabetes. Chronic high blood glucose is one of the most important contributors.

When glucose levels remain elevated over time, cells experience increased oxidative stress. This process creates harmful molecules called free radicals, which can damage proteins, fats, and DNA. As a result, tissues may lose function more quickly.

Inflammation also plays a major role. People with type 2 diabetes often have persistent low-grade inflammation. Although inflammation is part of the body’s natural defence system, chronic inflammation can gradually injure healthy tissues. Researchers often call this process “inflammaging,” which describes the overlap between inflammation and aging.

Another key factor is cellular senescence. Senescent cells no longer divide normally, but they remain active in the body. Instead of helping tissues repair themselves, they release inflammatory signals that may harm nearby cells. Therefore, diabetes may encourage the build-up of these dysfunctional cells and contribute to faster tissue aging.

In addition, diabetes is linked with changes in DNA methylation. These epigenetic changes affect how genes behave without changing the genetic code itself. Over time, these shifts may influence aging pathways and increase the risk of chronic disease.

Epigenetic Clocks and New Aging Biomarkers

One of the most promising areas in aging science is the development of epigenetic clocks. These tools estimate biological age by analysing DNA methylation patterns across the genome.

One widely studied biomarker is PhenoAge, which combines clinical measures and epigenetic information to estimate biological aging. Researchers have found that people with diabetes may show higher biological age scores than people without diabetes who are the same chronological age.

Another important tool is DunedinPACE. Rather than estimating total biological age, DunedinPACE measures the pace of aging. In other words, it helps researchers see how quickly physiological decline may be happening over time.

These biomarkers offer important advantages. Instead of waiting many years to observe complications, investigators can measure aging-related changes much earlier. Consequently, scientists may be able to study whether treatments, lifestyle changes, or weight loss interventions influence biological aging before traditional outcomes appear.

Furthermore, these tools may help explain why some people with diabetes develop complications more quickly than others. Even when glucose control looks similar, differences in inflammation, metabolic stress, and epigenetic aging may affect long-term outcomes.

Can Modern Diabetes Therapies Slow Biological Aging?

Although research is still developing, there is growing interest in whether certain diabetes treatments may help slow the accelerated aging processes seen in people with diabetes.

Improved glucose control remains the foundation of diabetes care. Lowering long-term glucose exposure may reduce oxidative stress, inflammation, and cellular damage. Therefore, keeping glucose levels in a healthy target range remains one of the most important ways to protect long-term health.

Researchers are also studying newer therapies, including GLP-1 receptor agonists and SGLT2 inhibitors. These medications have shown benefits beyond glucose lowering, including cardiovascular and kidney protection. As a result, scientists are asking whether they may also influence aging pathways.

Early evidence suggests that these therapies may help reduce inflammation, improve metabolic function, and support cellular resilience. However, more research is needed before experts can say whether they directly slow biological aging.

Lifestyle changes remain equally important. Regular physical activity, healthy nutrition, weight management, quality sleep, and smoking cessation may all support healthier aging. In fact, these habits can influence inflammation, insulin sensitivity, epigenetic aging, and overall healthspan.

As aging biomarkers become more refined, future diabetes care may focus not only on glucose targets but also on protecting long-term cellular health.

Conclusion

The emerging science surrounding diabetes-related biological aging is reshaping how researchers view the disease. Rather than being only a disorder of glucose regulation, diabetes may influence aging pathways that affect nearly every organ system.

Advanced biomarkers such as PhenoAge and DunedinPACE are helping scientists understand how chronic metabolic stress may alter biological age. Meanwhile, growing evidence points to inflammation, oxidative stress, cellular senescence, and epigenetic changes as key contributors to faster aging in people with diabetes.

Although many questions remain, this research offers a more complete view of diabetes and long-term health. In the future, slowing biological aging may become an important goal alongside glucose control, cardiovascular protection, and complication prevention.

FAQs

What is accelerated biological aging in diabetes?

This term refers to the observation that people with diabetes may experience cellular and molecular aging changes that occur more rapidly than expected for their chronological age.

How is biological age different from chronological age?

Chronological age measures how many years a person has lived. Biological age reflects how well the body’s cells, tissues, and organs are functioning.

What are epigenetic clocks?

Epigenetic clocks are tools that estimate biological age by measuring DNA methylation patterns across the genome.

What is DunedinPACE?

DunedinPACE is a biomarker that measures the pace of biological aging, rather than simply estimating a person’s biological age.

Can diabetes treatments slow biological aging?

Some treatments and lifestyle changes may affect aging-related pathways, including inflammation and metabolic stress. However, more research is needed to confirm whether they directly slow biological aging.

Disclaimer: This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.

https://www.diabetesincontrol.com/accelerated-biological-aging-in-diabetes/ 

New Coffee Chemicals Show Promise for Managing Type 2 Diabetes

 From usnews.com

Coffee may do more than boost energy.

New research suggests that certain compounds found in roasted coffee beans could help slow how quickly sugar enters the bloodstream, a finding that could one day support new foods aimed at managing type 2 diabetes.

Scientists have identified three previously unknown compounds in roasted coffee that strongly block α-glucosidase, an enzyme that helps the body break down carbohydrates during digestion.

That enzyme plays a key role in how fast sugar enters the blood. Slowing it down can help prevent spikes in blood sugar.

The research was led by Minghua Qiu at the Kunming Institute of Botany, Chinese Academy of Sciences, and published in the journal Beverage Plant Research.

The findings add to the growing evidence that coffee may offer health benefits beyond basic nutrition (and taste).

                                                                                   HealthDay

Finding helpful compounds in foods is challenging because they contain thousands of interlinked chemicals.

To tackle this, the research team used advanced lab tools, including nuclear magnetic resonance (NMR) and liquid chromatography-mass spectrometry (LC-MS/MS), to carefully analyze roasted Coffea arabica beans.

Using a three-step screening process, the scientists narrowed down the most chemically active portions of the coffee extract.

After further testing and purification, they isolated three new compounds, which they named caffaldehydes A, B and C.

All three compounds strongly blocked α-glucosidase. Their effectiveness, which was measured by IC₅₀ values, ranged from 45.07 to 17.50 micromoles, making them more potent than acarbose, a drug commonly used to treat diabetes. (The lower the IC₅₀ value, the greater the potency.)

The team then used additional mass spectrometry tools to search for harder-to-detect substances. That analysis uncovered three more previously unknown compounds.

Together, the results show that the researchers’ method can uncover meaningful health-related compounds in complex foods like coffee.

The findings suggest that coffee-based ingredients could one day be developed to help support blood sugar control. Researchers say future studies will test whether these compounds are safe and effective in living organisms.

https://www.usnews.com/news/health-news/articles/2026-01-19/new-coffee-chemicals-show-promise-for-managing-type-2-diabetes

Scientists Discover a Surprising New Way To Fight Type 2 Diabetes

From scitechdaily.com

Gut microbes produce D-lactate that worsens metabolism. A trap for it restores healthier blood sugar and liver function

A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. 

The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease.

Scientists in Canada discovered that gut microbes fuel liver dysfunction, but stopping this process at its source dramatically improved metabolic health in mice. Credit: Shutterstock

Microbial molecule disrupts metabolism

Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice.

“This is a new twist on a classic metabolic pathway,” says Jonathan Schertzer, senior and corresponding author and professor in the Department of Biochemistry and Biomedical Sciences at McMaster. “We’ve known for nearly a century that muscles and the liver exchange lactate and glucose — a process called the Cori cycle. What we’ve discovered is a new branch of that cycle, where gut bacteria are also part of the conversation.”

In 1947, Carl Ferdinand Cori and Gerty Theresa Cori were awarded the Nobel Prize in Physiology or Medicine for showing how muscle-generated lactate fuels the liver to make blood glucose, which then cycles back to power muscle activity. Their work established the foundation for understanding how muscles use one form of lactate (L-lactate) and how the liver uses blood glucose in a tightly coordinated fuel exchange.

The Canadian team has now shown that obese mice — and even humans with obesity — carry elevated levels of a different molecule, D-lactate, in their blood. Unlike the well-studied L-lactate produced by muscles, D-lactate largely originates from gut bacteria and was found to raise blood sugar and liver fat more strongly.

Blocking D-lactate with a substrate trap

To stop this, the researchers created a “gut substrate trap” — a safe, biodegradable polymer that binds to D-lactate in the gut and prevents it from being absorbed. Mice fed this trap had lower blood glucose, less insulin resistance, and reduced liver inflammation and fibrosis — all without changing their diet or body weight.

“This is a completely new way to think about treating metabolic diseases like type 2 diabetes and fatty liver disease. Instead of targeting hormones or the liver directly, we’re intercepting a microbial fuel source before it can do harm,” says Schertzer, a member of the Centre for Metabolism, Obesity, and Diabetes Research (MODR) and Farncombe Family Digestive Health Research Institute at McMaster. Schertzer holds a Canada Research Chair in Metabolic Inflammation.

Reference: “Gut substrate trap of D-lactate from microbiota improves blood glucose and fatty liver disease in obese mice” by Han Fang, Fernando F. Anhê, Dana Kukje Zada, Nicole G. Barra, Rodrigo Rodrigues e-Lacerda, Breanne T. McAlpin, Ryan Wylie, Line Berthiaume, Étienne Audet-Walsh, Conor O’Dwyer, Peyman Ghorbani, Morgan D. Fullerton, Claudia Gagnon, André Tchernof, André Marette and Jonathan D. Schertzer, 29 July 2025, Cell Metabolism.
DOI: 10.1016/j.cmet.2025.07.001

https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/

What’s Next in Diabetes Care: Innovations and Insights

From beyondtype1.org

By Melanie Batchelor, MHS, RD, LDN, CDCES & Dan Trecroci 

The Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Amsterdam was buzzing with breakthroughs across the diabetes spectrum. 

Here’s a simple wrap-up of three themes that stopped us in our tracks.

Theme 1: Looking beyond the type of diabetes

No longer one-size-fits-all, new tech and meds are tackling every type of diabetes.

For years, type 1 diabetes (T1D) and type 2 diabetes (T2D) lived in separate worlds, with different meds and tech. 

At ATTD, we saw those walls coming down. It’s less about the type and more about what helps.

Insulin pumps for type 2 diabetes

• Automated insulin delivery, once only for people with T1D, is now working wonders for folks with T2D as well. 
• In one study, A1c dropped from 8.2% to 7.3% in just 13 weeks. 
• People needed less insulin.

Insulin pumps during pregnancy

In the UK, women with T1D are using automated insulin pumps (aka automated insulin delivery—or AID—systems) throughout pregnancy—a time when blood sugar can be chaotic. 

The result? 

• More time in range.
• Healthier weight gain.
• Smoother transitions into postpartum. 

Moms loved the tech so much, they kept using it after giving birth.

CGMs for prediabetes

• People without diabetes are now trying out continuous glucose monitors (CGMs) like the new over-the-counter Dexcom Stelo. 
• Real-time data helps them understand how food, sleep and exercise impact blood sugar. 
• 84% of users with prediabetes said they’d give it a go.

Gender equity in diabetes tech

• The Medtronic 780G insulin pump is helping both men and women stay in range—even during hormonal shifts like menstruation. 
• It’s adaptive, smart and proof that tech can help close the gender gap in diabetes care.
• Both men and women hit 72% time in range on the 780G pump.

• For women, the pump helped smooth out glucose swings during menstrual cycles.

GLP-1s for… everything?

• GLP-1 meds like tirzepatide and semaglutide are branching out.
• Originally for diabetes and weight loss, now they’re showing benefits for heart failure, sleep apnoea, joint pain and liver disease. 
  • Tirzepatide helps people with heart failure breathe easier and avoid hospital stays.
  • Semaglutide helps reduce knee pain and protects kidneys, even in people without diabetes.
    • It can even reverse prediabetes in some people—81% of those taking it had normal blood sugar again.
  • Survodutide (a new cousin of semaglutide) is helping with a liver condition called MASH.
  • Tirzepatide also significantly reduced sleep apnoea symptoms by more than 60%.

GLP-1s in type 1 diabetes? Yup.

Tirzepatide has shown promising benefits for people with T1D, including:

• Helping with weight loss.
• Improving glucose control.
• Enhancing kidney and heart health, even after accounting for weight loss.

This could be a major shift in how we think about GLP-1 use for T1D.

Bottom line: 

• We’re entering a new era where tools and medications are transitioning from one “type” of diabetes to another. 

• These advancements are even extending into other health conditions.

• The best tech or med? It’s the one that works for you.

Theme 2: TIR, TITR and the TING thing

Are we aiming for good blood sugars… or perfect ones?

We’ve all heard of time in range (TIR): the percent of time blood sugar stays between 70 and 180 mg/dL. 

Now, two new terms are popping up:

• TITR (Time in Tight Range): 70–140 mg/dL
• TING (Time in Normal Glycemia): 70–99 mg/dL

What’s normal blood sugar for someone without diabetes?

• A recent study looked at 153 people (ages 7 to 80) who don’t have diabetes.
• They spent 96% of the day in the “tight range” of 70–140 mg/dL.
• Another study found that
  • People without diabetes: only 15 minutes/day over 180 mg/dL.
  • People with prediabetes: about 45 minutes/day over 180 mg/dL.
  • People with diabetes: around 6.5 hours per day over 180 mg/dL (that’s about 27% of the time!).

Why this matters

• Some experts now wonder, should people with diabetes aim for tighter ranges too?
• The Medtronic 780G system shows that people with diabetes using tech can hit about 50% TITR.
• But if the target is 96% (like in people without diabetes), and someone gets 50%—is that a failing grade?

What makes it harder for people with diabetes?

That kind of pressure could actually make diabetes management harder.

Unlike someone without diabetes, people with diabetes have to juggle:

• Insulin doses
• Meals & snacks
• Hormones
• Illness
• Stress
• Sleep
• Exercise
• Technology

And all of this… every single day.

So being in the “normal” range all the time? Not always realistic.

Why doctors are talking about TING

• Studies show the more time in normal ranges, the lower the risk of complications.
• Some experts see TING as a more “precise” goal—others argue not everyone wants (or needs) to aim for perfection.

Theme 3: Toward a cure

It’s not sci-fi anymore—real people are already seeing real progress.

This year, one in four sessions at ATTD was focused on curing T1D.

And the energy was electric.

Here’s a peek at what’s happening in labs, hospitals and trials

Whole pancreas transplants

• Effective, but big surgery and lifelong meds. Only for a small number of people.

Islet cell transplants

• Instead of the whole pancreas, just the insulin-making cells are transplanted. 
• Some new versions include “shields” to protect them from immune attacks—no need for full immunosuppression.

Encapsulation devices

• Think of them as high-tech armour for new beta cells—they keep the bad stuff (like an immune system in attack mode) out and let the good stuff in.

Immune system reboot

• Researchers are developing ways to “retrain” the immune system so it stops attacking the pancreas in the first place.

A new era in diabetes care: Hope for the future

From expanding treatment options to ground-breaking research, progress is happening. 

With each breakthrough, we move closer to better care, improved quality of life and—one day—a cure.

https://beyondtype1.org/whats-next-in-diabetes-care-innovations-and-insights/